KR20190012943A - Health functional food composition for Burning mouth syndrome and Stomatitis Treatment and Prevention - Google Patents
Health functional food composition for Burning mouth syndrome and Stomatitis Treatment and Prevention Download PDFInfo
- Publication number
- KR20190012943A KR20190012943A KR1020170096705A KR20170096705A KR20190012943A KR 20190012943 A KR20190012943 A KR 20190012943A KR 1020170096705 A KR1020170096705 A KR 1020170096705A KR 20170096705 A KR20170096705 A KR 20170096705A KR 20190012943 A KR20190012943 A KR 20190012943A
- Authority
- KR
- South Korea
- Prior art keywords
- weight
- parts
- powder
- functional food
- stomatitis
- Prior art date
Links
- 208000003265 stomatitis Diseases 0.000 title claims abstract description 16
- 235000013376 functional food Nutrition 0.000 title claims abstract description 14
- 230000036541 health Effects 0.000 title claims abstract description 13
- 239000000203 mixture Substances 0.000 title claims abstract description 11
- 206010068065 Burning mouth syndrome Diseases 0.000 title abstract description 7
- 230000002265 prevention Effects 0.000 title description 3
- 239000000843 powder Substances 0.000 claims abstract description 56
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims abstract description 54
- 239000011787 zinc oxide Substances 0.000 claims abstract description 27
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 26
- 239000000284 extract Substances 0.000 claims abstract description 23
- 235000014360 Punica granatum Nutrition 0.000 claims abstract description 16
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 claims abstract description 16
- 229930003779 Vitamin B12 Natural products 0.000 claims abstract description 15
- 235000019163 vitamin B12 Nutrition 0.000 claims abstract description 15
- 239000011715 vitamin B12 Substances 0.000 claims abstract description 15
- 241000241413 Propolis Species 0.000 claims abstract description 14
- 229940069949 propolis Drugs 0.000 claims abstract description 14
- 235000002789 Panax ginseng Nutrition 0.000 claims abstract description 13
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 13
- 239000012141 concentrate Substances 0.000 claims abstract description 12
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 claims abstract description 11
- 235000002118 Vaccinium oxycoccus Nutrition 0.000 claims abstract description 11
- 235000004634 cranberry Nutrition 0.000 claims abstract description 11
- 240000001717 Vaccinium macrocarpon Species 0.000 claims abstract description 9
- 208000011580 syndromic disease Diseases 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 241000219991 Lythraceae Species 0.000 claims description 4
- 239000003826 tablet Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 235000014692 zinc oxide Nutrition 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 2
- 235000013402 health food Nutrition 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 235000015097 nutrients Nutrition 0.000 claims description 2
- 244000294611 Punica granatum Species 0.000 abstract description 13
- 235000013399 edible fruits Nutrition 0.000 abstract description 10
- 244000046101 Sophora japonica Species 0.000 abstract description 2
- 235000010586 Sophora japonica Nutrition 0.000 abstract description 2
- 206010006784 Burning sensation Diseases 0.000 description 9
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 8
- 239000011701 zinc Substances 0.000 description 8
- 229910052725 zinc Inorganic materials 0.000 description 8
- 210000000214 mouth Anatomy 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 206010030973 Oral discomfort Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 208000002720 Malnutrition Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 244000291414 Vaccinium oxycoccus Species 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 235000018343 nutrient deficiency Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 208000002670 vitamin B12 deficiency Diseases 0.000 description 2
- MZFOKIKEPGUZEN-AGCMQPJKSA-N (R)-methylmalonyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)[C@@H](C(O)=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MZFOKIKEPGUZEN-AGCMQPJKSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 208000028698 Cognitive impairment Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 208000004044 Hypesthesia Diseases 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 206010030247 Oestrogen deficiency Diseases 0.000 description 1
- 208000025157 Oral disease Diseases 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 206010040026 Sensory disturbance Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 206010048259 Zinc deficiency Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 235000019463 artificial additive Nutrition 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 238000009534 blood test Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 208000010877 cognitive disease Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000034783 hypoesthesia Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000008897 memory decline Effects 0.000 description 1
- 230000009245 menopause Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 208000030194 mouth disease Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 238000010422 painting Methods 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000003075 phytoestrogen Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000014860 sensory perception of taste Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/704—Vitamin B
- A23V2250/706—Vitamin B12
Abstract
Description
본 발명은 구강작열감 증상을 치료하고 구내염 발생을 예방하는 건강기능식품에 관한 것이다.The present invention relates to a health functional food for treating oral burning sensation symptoms and preventing stomatitis.
구강작열감 증후군(Burning mouth syndrome)은 특별한 원인 없이 혀나 구강의 점막부위에서 화끈거리거나 따끔거림, 감각 이상 등의 통증을 느끼는 증상을 말한다.Burning mouth syndrome refers to the symptoms of burning, tingling, and sensory disturbances in the mucous membranes of the tongue and mouth without any special cause.
주로 중년의 폐경기 여성에서 호발하는 것으로 알려져 있으나 여러 연령, 남녀 모두에서 나타날 수 있다. 전체 인구의 약 5% 정도가 구강작열감 증후군 환자이며, 구강작열감 증후군 환자들은 침(타액)의 분비량이 저하되며, 이에 따라 치주염, 구내염 등의 각종 감염증이 발생하기 쉽다.It is known to occur mainly in middle-aged menopausal women, but it can occur in many ages, both men and women. Approximately 5% of the total population is suffering from burning mouth syndrome. In patients with burning mouth syndrome, the amount of saliva secretion is reduced, and various infections such as periodontitis and stomatitis are likely to occur.
구강작열감 증후군의 정확한 원인은 정확히 밝혀지지 않았으나, 스트레스, 구강건조증, 갑상선기능저하증, 빈혈, 당뇨, 호르몬 이상, 구강점막변화, 말초 신경 변화, 비타민과 무기질 등 영양소 부족 등이 관계되는 것으로 추정되고 있다.The exact cause of oral burning syndrome has not been clearly elucidated, but it is presumed that stress, dry mouth, hypothyroidism, anemia, diabetes, hormonal abnormalities, oral mucosal changes, peripheral nerve changes, and lack of nutrients such as vitamins and minerals .
현재 구강작열감 증후군 치료를 위해 아미트리프틸린과 클로나제팜와 같은 향정신성 의약을 투여하고 있으나 의사의 처방이 필요하고 완치는 쉽지 않으며, 입마름, 변비, 요도 막힘 등의 부작용이 발생하는 문제가 있다. 여러 선행 연구들에 따르면, 구강작열감을 호소하는 환자 중 다수가 아연, 비타민B12 결핍군에 해당하거나, 정상범위 중 하위군에 해당하는 것으로 밝혀졌다. 이에 따라 임상적으로 구강작열감의 치료를 위해 신경변병성 통증의 진단 및 처방 이전에 영양소 부족을 해결하려는 노력이 행해지고 있다. 그러나 현재 구강 작열감 환자의 영양소 부족을 해결하기 위해 최적화된 솔루션이 없어 환자들이 여러 약을 중복하여 복용하고 있는 실정이다.Currently, psychotropic drugs such as amitriptyline and clonazepam are administered for the treatment of burning mouth syndrome. However, it is necessary to take a doctor's prescription and it is not easy to cure, and side effects such as mouth dryness, constipation, and urethral blockage occur. According to several previous studies, the majority of patients complaining of burning mouths were found to be zinc, vitamin B12 deficient, or subgroup of normal range. Clinically, there are efforts to solve the nutritional deficiency before diagnosis and prescription of neurotransmitter pain for the treatment of burning sensation in the mouth. However, there is currently no optimal solution to address the nutritional deficiency of burning patients, and patients are taking multiple medications.
따라서, 의사의 처방이 필요 없고 부작용이 없으며 구내염 및 구강작열감 증상의 치료를 위한 건강기능식품의 개발이 절실히 요구되고 있다.Therefore, there is a desperate need for the development of a health functional food for the treatment of symptoms of stomatitis and oral burning without requiring a doctor's prescription, no side effects.
본 발명이 이루고자 하는 기술적 과제는 구강작열감 치료하고 구내염 발생을 예방하는 건강기능식품을 제공하자고 한다.The present invention provides a health functional food for treating oral burning and preventing stomatitis.
이러한 과제를 해결하기 위하여 본 발명의 실시예에 따른 구강작열감 증후군과 구내염 치료 및 예방용 건강기능식품 조성물은 산화아연, 비타민B12, 석류농축분말, 프로폴리스추출분말, 홍삼농축액분말, 회화나무열매추출물, 크랜베리농축분말, 및 스테아린산마그네슘을 유효성분으로 포함한다. In order to solve these problems, the functional food composition for oral burning sensation syndrome and stomatitis according to an embodiment of the present invention comprises zinc oxide, vitamin B12, pomegranate concentrate powder, propolis extract powder, red ginseng concentrate powder, , Cranberry concentrated powder, and magnesium stearate as active ingredients.
상기 구강작열감 증후군과 구내염 치료 및 예방용 조성물은 상기 산화아연 100 중량부에 대해 상기 비타민B12는 2 내지 4 중량부, 상기 석류농축분말은 400 내지 450 중량부, 상기 프로폴리스추출분말은 0.05 내지 0.15 중량부, 상기 홍삼농축액분말은 9 내지 12 중량부, 상기 회화나무열매추출물은 9 내지 12 중량부, 상기 크랜베리농축분말은 9 내지 12 중량부, 및 상기 스테아린산마그네슘은 9 내지 12 중량부일 수 있다.The composition for treatment and prevention of oral burning sensation syndrome and stomatitis is characterized in that 2 to 4 parts by weight of the vitamin B12, 400 to 450 parts by weight of the pomegranate concentrated powder and 0.05 to 0.15 parts by weight of the propolis extract powder are contained in 100 parts by weight of zinc oxide, 9 to 12 parts by weight of the red ginseng concentrated powder, 9 to 12 parts by weight of the fruit extract, 9 to 12 parts by weight of the cranberry concentrated powder and 9 to 12 parts by weight of the magnesium stearate.
상기 산화아연 100 중량부에 대해 상기 비타민B12는 3 중량부, 상기 석류농축분말은 423.5 중량부, 상기 프로폴리스추출분말은 0.1 중량부, 상기 홍삼농축액분말은 10.6 중량부, 상기 회화나무열매추출물은 10.6 중량부, 상기 크랜베리농축분말은 10.6 중량부, 및 상기 스테아린산마그네슘은 10.6 중량부일 수 있다.3 parts by weight of the vitamin B12, 423.5 parts by weight of the pomegranate concentrated powder, 0.1 part by weight of the extracted propolis powder, and 10.6 parts by weight of the red ginseng concentrated powder were mixed with 100 parts by weight of the zinc oxide, 10.6 parts by weight of the cranberry-concentrated powder, 10.6 parts by weight of the cranberry-concentrated powder, and 10.6 parts by weight of the magnesium stearate.
본 발명의 실시예에 따른 구강작열감 증후군과 구내염 치료 및 예방용 건강기능식품은 건강식품 조성물을 분말, 캡슐, 정제, 서방정, 과립, 엑기스 또는 음료의 제형으로 제조된다.According to an embodiment of the present invention, the health functional food for oral burning sensation syndrome and stomatitis treatment and prevention is prepared by formulating a health food composition into a powder, a capsule, a tablet, a lozenge, a granule, an extract or a drink.
위에서 언급된 본 발명의 기술적 과제 외에도, 본 발명의 다른 특징 및 이점들이 이하에서 기술되거나, 그러한 기술 및 설명으로부터 본 발명이 속하는 기술분야에서 통상의 지식을 가진 자에게 명확하게 이해될 수 있을 것이다.Other features and advantages of the invention will be set forth in the description which follows, or may be obvious to those skilled in the art from the description and the claims.
이상과 같은 본 발명에 따르면 다음과 같은 효과가 있다. According to the present invention as described above, the following effects can be obtained.
본 발명은 구강작열감 증후군 치료에 도움이 되며, 구내염 발생을 예방할 수 있다.The present invention is useful in the treatment of oral burning sensation syndrome and can prevent the occurrence of stomatitis.
본 발명은 최대 직경이 1cm이하의 알약으로 제작됨으로써 복용의 편의성을 높일 수 있다.The present invention can be made into a tablet having a maximum diameter of 1 cm or less, thereby enhancing convenience of taking.
이하, 본 발명의 목적이 구체적으로 실현될 수 있는 바람직한 실시예를 상세히 설명한다. 본 실시예를 설명함에 있어서, 동일 구성에 대해서는 동일 명칭이 사용되며 이에 따른 부가적인 설명은 생략하기로 한다.Hereinafter, preferred embodiments in which the object of the present invention can be specifically realized will be described in detail. In describing the present embodiment, the same names are used for the same components, and further description thereof will be omitted.
본 발명의 일 실시예에 따른 구강작열감 증후군과 구내염 치료 및 예방용 건강기능식품 조성물은 산화아연, 비타민B12, 석류농축분말, 프로폴리스추출분말, 홍삼농축액분말, 회화나무열매추출물, 크랜베리농축분말, 및 스테아린산마그네슘을 포함하여 구성된다.According to one embodiment of the present invention, the health functional food composition for treating or preventing oral inflammation and stomatitis includes zinc oxide, vitamin B12, pomegranate concentrated powder, propolis extract powder, red ginseng concentrate powder, And magnesium stearate.
이때, 건강기능식품 조성물은 상기 산화아연 100 중량부에 대해 상기 비타민B12는 2 내지 4 중량부, 상기 석류농축분말은 400 내지 450 중량부, 상기 프로폴리스추출분말은 0.05 내지 0.15 중량부, 상기 홍삼농축액분말은 9 내지 12 중량부, 상기 회화나무열매추출물은 9 내지 12 중량부, 상기 크랜베리농축분말은 9 내지 12 중량부, 및 상기 스테아린산마그네슘은 9 내지 12 중량부로 이루어질 수 있다.In the health functional food composition, 2 to 4 parts by weight of the vitamin B12, 400 to 450 parts by weight of the pomegranate concentrated powder, 0.05 to 0.15 part by weight of the extracted propolis powder, 9 to 12 parts by weight of the concentrate powder, 9 to 12 parts by weight of the fruit extract, 9 to 12 parts by weight of the cranberry concentrated powder and 9 to 12 parts by weight of the magnesium stearate.
1. 산화아연 1. Zinc oxide
산화아연은 세포의 분화, 증식에 필수적인 역할을 하여 성장, 조직 및 골격형성, 생식, 면역 기능에 중요한 역할을 하며, 아연의 황산화작용으로 피부의 노화를 지연시킬 수 있다. 특히 산화아연이 결핍될 경우 맛과 냄새의 감각이 저하되며 입맛을 잃게 된다. Zinc oxide plays an essential role in the differentiation and proliferation of cells, and plays an important role in growth, tissue and skeleton formation, reproduction and immune function, and it can delay the aging of the skin due to the sulfation of zinc. Especially, when zinc oxide is deficient, the sense of taste and smell is lowered and the taste is lost.
2. 비타민B12 2. Vitamin B12
비타민B12은 수용성 비타민으로 코발라민으로 불리며 적혈구 생성, 신경기능, DNA 합성에 필수적인 성분으로서, 메티오닌 합성과 L-메틸말로닐-보조효소A-뮤타제(L-methylmalonyl-CoA mutase) 합성의 보조인자로 작용한다. 또한 신경기능을 위한 수초(미엘린)의 유지에 필요한 성분이다.Vitamin B12 is a water-soluble vitamin called cobalamin that is essential for red blood cell formation, nerve function, and DNA synthesis. It acts as a cofactor for the synthesis of methionine and the synthesis of L-methylmalonyl-CoA mutase. do. It is also a necessary component for the maintenance of myelin for nerve function.
특히, 비타민B12 결핍될 경우 신체 말단의 따끔거림, 무감각, 운동장애, 인지능력 장애 등의 신경장애 증세가 나타날 수 있다.In particular, vitamin B12 deficiency may cause symptoms of neuropathy such as tingling at the extremities, numbness, movement disorders, cognitive impairment, and the like.
이러한 비타민B12는 산화아연 100 중량부에 대해 2 내지 4 중량부가 포함되어 이루어질 수 있으며, 산화아연 100 중량부에 대해 3 중량부로 포함되어 이루어지는 것이 바람직하다.Such vitamin B12 may be contained in an amount of 2 to 4 parts by weight based on 100 parts by weight of zinc oxide, and preferably includes 3 parts by weight based on 100 parts by weight of zinc oxide.
3. 석류농축분말 3. Pomegranate concentrate powder
석류(Pomegranate, Punica granatum L.)는 석류나무과(Punicaceae)에 속하는 석류나무의 열매로서, 과육에는 당질(포도당·과당), 시트르산 등의 유기산 및 소량의 수용성 비타민(B1?B2?나이아신) 등이 포함되어 있고, 과피에는 다량의 탄닌이 포함되어 있으며, 씨에는 식물성 에스트로겐(phytoestrogen) 등의 성분이 포함되어 있다고 알려져 있다. 수용성 비타민 B1은 운동신경과 시신경에 효과가 있고, 비타민 B2는 지능저하와 기억력 감퇴, 알츠하이머 등을 예방할 수 있으며, 나이아신은 체내의 에너지대사에 꼭 필요하며 구강염과 구내염에 효과적이고, 탄닌은 소화액의 분비를 자극시켜 입맛을 돋우고 인체의 에너지대사를 도와 피로를 빠르게 회복시키며, 식물성 에스트로겐은 여성의 갱년기 장애에 좋다고 알려져 있다.Pomegranate (Punica granatum L.) is a fruit of the pomegranate tree belonging to the pomegranate family (Punicaceae). It contains organic acids such as carbohydrate (glucose · fructose), citric acid and small amount of water soluble vitamins (B1? B2? Niacin) , The skin contains a large amount of tannins, and seeds are known to contain components such as phytoestrogen. Water-soluble vitamin B1 has effects on motor neurons and optic nerve. Vitamin B2 can prevent intellectual deterioration, memory decline, Alzheimer's, etc. Niacin is essential for energy metabolism in the body and is effective for oral salt and stomatitis. Stimulates the secretion of appetite, metabolism of the body to help the body quickly restore fatigue, vegetable estrogen is known to be good for women's menopausal disorders.
석류농축분말은 석류의 과피, 과육 및 씨의 착즙액으로부터 생성한 추출분말이다. The pomegranate concentrate powder is an extract powder produced from the fruit of pomegranate, pulp and seed juice.
이러한 석류농축분말은 산화아연 100 중량부에 대해 400 내지 450 중량부가 포함되어 이루어질 수 있으며, 산화아연 100 중량부에 대해 423.5 중량부로 포함되어 이루어지는 것이 바람직하다.The pomegranate-concentrated powder may be composed of 400 to 450 parts by weight based on 100 parts by weight of zinc oxide, and preferably contains 423.5 parts by weight based on 100 parts by weight of zinc oxide.
4. 프로폴리스추출분말 4. Propolis extract powder
프로폴리스(propolis)란 꿀벌이 전나무, 버드나무 등 각종 나무로부터 모은 다양한 수액과 꽃에서 모은 꽃가루에 꿀벌 자신의 밀랍(beeswax) 등 분비물을 이용하여 만든 물질이다. Propolis is a substance made by using the bees' own beeswax and other secretions in a variety of sap and pollen collected from various trees collected from various trees such as fir and willow trees.
프로폴리스추출분말은 프로폴리스 추출물로부터 생성한 추출분말로, 항균 및 항산화 작용을 한다. Propolis extract powder is an extract powder produced from propolis extract and has antibacterial and antioxidant activity.
이러한 프로폴리스추출분말은 산화아연 100 중량부에 대해 0.05 내지 0.15 중량부가 포함되어 이루어질 수 있으며, 산화아연 100 중량부에 대해 0.1 중량부로 포함되어 이루어지는 것이 바람직하다.The propolis extract powder may be contained in an amount of 0.05 to 0.15 part by weight based on 100 parts by weight of zinc oxide and may be included in an amount of 0.1 part by weight based on 100 parts by weight of zinc oxide.
5. 홍삼농축액분말 5. Red ginseng concentrate powder
홍삼은 동의보감에서 "원기를 크게 보하고 폐를 튼튼히 하며 비장을 좋게 하고 심장을 튼튼하게 해준다."라고 하였다. 특히 홍삼농축액분말은 사포닌 함량이 g당 105mg 이상으로 영양적으로 우수하고 향이 부드럽고 진하다.The red ginseng in the Dongbibogam said, "I see a great pleasure, strengthen my lungs, strengthen my spleen and strengthen my heart." In particular, the red ginseng concentrate powder has a saponin content of 105 mg or more per gram and is nutritionally excellent, and the fragrance is smooth and thick.
홍삼농축액분말은 면역력을 증진시키고, 피로 및 기억력 개선에 도움을 줄 수 있다. Red ginseng concentrate powder can improve immunity, improve fatigue and memory.
이러한 홍삼농축액분말은 산화아연 100 중량부에 대해 9 내지 12 중량부가 포함되어 이루어질 수 있으며, 산화아연 100 중량부에 대해 10.6 중량부로 포함되어 이루어지는 것이 바람직하다.The red ginseng concentrate powder may be contained in an amount of 9 to 12 parts by weight with respect to 100 parts by weight of zinc oxide, and may preferably include 10.6 parts by weight with respect to 100 parts by weight of zinc oxide.
6. 회화나무열매추출물 6. Painted fruit extract
회화나무열매추출물(Sophora Japonica Fruit Extract)은 회화나무의 열매에서 추출한 것으로, 여성 호르몬인 에스트로겐 부족으로 인해 발생하는 갱년기 증상을 개선하는데 도움을 준다. Sophora Japonica Fruit Extract is extracted from the fruit of the painting tree and helps to improve the symptoms of menopause caused by estrogen deficiency, a female hormone.
이러한 회화나무열매추출물은 산화아연 100 중량부에 대해 9 내지 12 중량부가 포함되어 이루어질 수 있으며, 산화아연 100 중량부에 대해 10.6 중량부로 포함되어 이루어지는 것이 바람직하다.The fruit extract may be contained in an amount of 9 to 12 parts by weight based on 100 parts by weight of zinc oxide, and preferably contains 10.6 parts by weight per 100 parts by weight of zinc oxide.
7. 크랜베리농축분말 7. Cranberry concentrated powder
크랜베리농축분말은 월귤류에 속하는 열매인 크랜베리의 추출분말로서, 크랜베리는 노화 방지, 대장균 감염 예방, 요도염 예방에 효과가 있으며, 특히, 구강 질환 예방에 효과가 있다. The cranberry-concentrated powder is an extract powder of cranberry, a fruit belonging to the manganese. The cranberry is effective in preventing aging, preventing E. coli infection, and preventing urethritis. Especially, it is effective for preventing oral disease.
이러한 크랜베리농축분말은 산화아연 100 중량부에 대해 9 내지 12 중량부가 포함되어 이루어질 수 있으며, 산화아연 100 중량부에 대해 10.6 중량부로 포함되어 이루어지는 것이 바람직하다.The cranberry-concentrated powder may be contained in an amount of 9 to 12 parts by weight based on 100 parts by weight of zinc oxide, and preferably contains 10.6 parts by weight per 100 parts by weight of zinc oxide.
8. 스테아린산마그네슘 8. Magnesium stearate
스테아린산마그네슘은 스테아린과 마그네슘을 결합한 합성첨가물로, 스테아린산마그네슘은 산화아연 100 중량부에 대해 9 내지 12 중량부가 포함되어 이루어질 수 있으며, 산화아연 100 중량부에 대해 10.6 중량부로 포함되어 이루어지는 것이 바람직하다.Magnesium stearate is a synthetic additive in which stearin and magnesium are combined, and magnesium stearate is contained in an amount of 9 to 12 parts by weight based on 100 parts by weight of zinc oxide. It is preferable that magnesium stearate is contained in an amount of 10.6 parts by weight based on 100 parts by weight of zinc oxide.
본 발명은 상기와 같은 조성물을 사용하여 분말, 캡슐, 정제, 서방정, 과립, 엑기스 또는 음료의 형태로 제조하여 건강기능식품으로 제품화 할 수 있다. 특히, 본 발명에 따른 건강기능식품은 구강작열감 또는 구내염을 가지고 있으며 연하장애를 가지고 있는 65세 이상의 노인이 복용하기 용이하도록 직경 1cm 이하의 알약 형태로 제작되는 것이 바람직하다.The present invention can be manufactured into a health functional food by preparing it in the form of powder, capsule, tablet, sustained-release tablet, granule, extract or beverage using the above composition. In particular, the health functional food according to the present invention is preferably made in the form of a pill having a diameter of 1 cm or less so that the aged person aged 65 years or older having a mouth burning sensation or stomatitis and swallowing disorder can easily take it.
이하에서는 실험예를 통하여 본 발명의 효과에 대해 설명한다.Hereinafter, the effects of the present invention will be described with reference to experimental examples.
[실험예 1] [Experimental Example 1]
실험예 1에서는 점막질환을 가진 368명 환자를 대상으로 조사한 결과, 368명 환자의 혈청내 아연의 농도가 정상인에 비해 통계적으로 유의하게 낮음을 확인하였다. In Experimental Example 1, 368 patients with mucosal diseases were examined and it was found that the concentration of zinc in the serum of 368 patients was statistically significantly lower than that of normal persons.
재발성 아프타 구내염을 치료를 위하여 20명의 환자에게 하루 220mg의 아연을 한 달간 경구 투여한 군에서 대조군에 비해 혈청내 아연, 알부민 농도가 높아졌고, 궤양은 감소하여 3 개월간 재발하지 않았다. To treat recurrent aphthous stomatitis, oral administration of 220 mg of zinc per day to 20 patients showed a higher serum zinc and albumin concentration than the control group, and the ulcer was decreased and did not recur for 3 months.
[실험예 2][Experimental Example 2]
실험예 2에서는 구강작열감을 느끼는 276명 환자를 대상으로 혈청아연 농도를 조사한 결과, 74명(26.8%)에서 낮은 농도를 보였다. In Experimental Example 2, serum zinc concentration was low in 74 patients (26.8%) in 276 patients who experienced burning sensation in oral cavity.
산화아연 14.1mg/day을 6개월간 섭취한 후에 그 효능에 대하여 구강내 불쾌감 지수를 평가하여 표 2에 표시하였다. 이때, 불쾌감 지수는 0~10 단계로, 10이 가장 불편함을 느끼는 지수이며, 0이 가장 편안함을 느끼는 지수이다.After ingesting zinc oxide 14.1 mg / day for 6 months, the oral discomfort index was evaluated for its efficacy and shown in Table 2. At this time, discomfort index is 0 ~ 10, 10 is the most discomfort index, and 0 is the most comfortable index.
상기 표 1로부터 구강작열감 증후군 환자가 산화아연을 섭취한 경우 구강 내 불쾌감이 줄어들었음을 확인하였다. From Table 1 above, it was confirmed that oral ingestion of zinc oxide reduced oral discomfort.
[실험예 3][Experimental Example 3]
실험예 3에서는 입안의 작열감으로 내원한 82명의 환자를 검사한 결과, 38명의 환자에서 혈액검사상 아연 또는 비타민B12가 결핍 또는 낮은 농도(정상 하위 10%)를 보였다. In Experiment 3, eighty patients who visited the hospital due to burning sensation in their mouths were examined. In 38 patients, there was a deficiency or low concentration (normal lower 10%) of zinc or vitamin B12 in the blood test.
아연 또는 비타민B12가 결핍되거나 낮은 38명의 환자에게 하루에 산화아연 40mg, 비타민B12 1000mcg 용량을 포함하는 건강기능식품을 1개월간 섭취하게 한 결과 입안의 불편감이 28명의 환자(74%)에서 개선되었다. In the 38 patients with zinc or vitamin B12 deficiency or in the lower 38 patients, a one-month intake of a healthy dietary supplement containing 40 mg of zinc oxide and 1000 mcg of vitamin B12 was improved in 28 patients (74%) .
Claims (4)
상기 산화아연 100 중량부에 대해 상기 비타민B12는 2 내지 4 중량부, 상기 석류농축분말은 400 내지 450 중량부, 상기 프로폴리스추출분말은 0.05 내지 0.15 중량부, 상기 홍삼농축액분말은 9 내지 12 중량부, 상기 회화나무열매추출물은 9 내지 12 중량부, 상기 크랜베리농축분말은 9 내지 12 중량부, 및 상기 스테아린산마그네슘은 9 내지 12 중량부인 구강작열감 증후군과 구내염 치료 및 예방용 건강기능식품 조성물.The method according to claim 1,
2 to 4 parts by weight of the vitamin B12, 400 to 450 parts by weight of the pomegranate concentrated powder, 0.05 to 0.15 part by weight of the extracted propolis powder, 9 to 12 parts by weight of the red ginseng concentrated powder, Wherein the nutrient extract is 9 to 12 parts by weight, the cranberry concentrated powder is 9 to 12 parts by weight, and the magnesium stearate is 9 to 12 parts by weight.
상기 산화아연 100 중량부에 대해 상기 비타민B12는 3 중량부, 상기 석류농축분말은 423.5 중량부, 상기 프로폴리스추출분말은 0.1 중량부, 상기 홍삼농축액분말은 10.6 중량부, 상기 회화나무열매추출물은 10.6 중량부, 상기 크랜베리농축분말은 10.6 중량부, 및 상기 스테아린산마그네슘은 10.6 중량부인 구강작열감 증후군과 구내염 치료 및 예방용 건강기능식품 조성물.3. The method of claim 2,
3 parts by weight of the vitamin B12, 423.5 parts by weight of the pomegranate concentrated powder, 0.1 part by weight of the extracted propolis powder, and 10.6 parts by weight of the red ginseng concentrated powder were mixed with 100 parts by weight of the zinc oxide, 10.6 parts by weight of the cranberry powder, 10.6 parts by weight of the cranberry concentrated powder, and 10.6 parts by weight of the magnesium stearate is a health functional food composition for treating and preventing oral inflammation syndrome and stomatitis.
A health functional food for treating or preventing oral inflammation syndrome and stomatitis, wherein the health food composition according to any one of claims 1 to 3 is prepared in the form of a powder, a capsule, a tablet, a lozenge, a granule, an extract or a drink.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170096705A KR20190012943A (en) | 2017-07-31 | 2017-07-31 | Health functional food composition for Burning mouth syndrome and Stomatitis Treatment and Prevention |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170096705A KR20190012943A (en) | 2017-07-31 | 2017-07-31 | Health functional food composition for Burning mouth syndrome and Stomatitis Treatment and Prevention |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20190012943A true KR20190012943A (en) | 2019-02-11 |
Family
ID=65369963
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170096705A KR20190012943A (en) | 2017-07-31 | 2017-07-31 | Health functional food composition for Burning mouth syndrome and Stomatitis Treatment and Prevention |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20190012943A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021052551A3 (en) * | 2019-09-17 | 2021-05-27 | محمود جلال، | Gum base and safe, natural oral composition |
-
2017
- 2017-07-31 KR KR1020170096705A patent/KR20190012943A/en not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021052551A3 (en) * | 2019-09-17 | 2021-05-27 | محمود جلال، | Gum base and safe, natural oral composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5932624A (en) | Vitamin supplement composition | |
| US20070292493A1 (en) | Pharmaceutical composition and method for the transdermal delivery of calcium | |
| US20160000845A1 (en) | Extract of trigonella foenum-graecum | |
| KR102107387B1 (en) | Beverage composition for treating hangover comprising black ginseng extact | |
| KR20190000955A (en) | Composition for preventing or treating periodontal disease comprising extracts of herbal mixture | |
| CN112263606A (en) | Traditional Chinese medicine gargle and preparation method thereof | |
| AU4734999A (en) | Combination of zinc ions and vitamin C and method of making | |
| EP2106705B1 (en) | Use of a compound comprising a vegetable lectin, a proteolytic enzyme and a selenium compound for mucous membrane protection and relief of other symptoms experienced by cancer patients | |
| KR20020092082A (en) | Tonic composition | |
| KR101293645B1 (en) | Phamaceutical composition for prevention or treatment of nephritis | |
| KR20190012943A (en) | Health functional food composition for Burning mouth syndrome and Stomatitis Treatment and Prevention | |
| KR101045025B1 (en) | Pharmaceutical composition for preventing or treatment of asthma | |
| KR101010575B1 (en) | The composition for the atopic dermatitis improving with vinegar | |
| EP3672589A1 (en) | Combination product for relieving the symptoms associated with upper respiratory tract infections | |
| AU2019101234B4 (en) | Formulation and method of use | |
| JP2003002831A (en) | Ameliorating agent for female hormone abnormality disorder | |
| JP2002238496A (en) | Medical health food | |
| CN112425703A (en) | Oral health improving product containing plant exosomes | |
| CN110051723A (en) | A kind of fructus hippophae mouthspray and preparation method thereof | |
| KR20210157987A (en) | Food composition for relieving hangover and improving hepatic function | |
| TW201408296A (en) | Composition and use for increasing T cells | |
| US20030170327A1 (en) | Vitamin and zinc monomethionine compositions | |
| CN1171594C (en) | Composition containing pearl powder and ascorbic acid | |
| WO2022091023A1 (en) | Combination of active ingredients, compositions containing it and their use to sustain and strengthen the immune system | |
| KR20040031799A (en) | Pharmaceutical composition containing the concentrate of Bando Deep Ocean Water having antiallergical activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E902 | Notification of reason for refusal | ||
| E601 | Decision to refuse application |